Mr. Kango is an experienced executive with more than 25 years of experience in the pharmaceutical and biotechnology industries. He has been instrumental in successfully transforming earlier stage organizations to later-stage development and commercial global biotech companies. Mr. Kango currently serves on the board of directors of MEI Pharma and Infinity Pharmaceuticals. Prior to joining Tmunity Therapeutics, he was the Executive Vice President and CCO at Acceleron Pharma. Under his leadership the team launched Reblozyl for MDS and B-Thalassemia, led rare disease franchises in pulmonary and neuromuscular disorders, and established N.America and international presence for Acceleron. He played a key leadership role in Acceleron’s $11.5B acquisition by Merck in late 2021. Mr. Kango has additionally led multiple global product launches across several therapeutic areas including oncology-hematology, rare diseases, immunology, and virology. Previously Mr. Kango was vice president of global commercial development for oncology at AbbVie and the co-chair of the oncology therapy area committee which oversaw strategy and development of the broad oncology-hematology portfolio from research to late stage and approval. He also served as the executive vice president and chief commercial officer at Infinity Pharmaceuticals. From 2011-2015, Mr. Kango served as vice president/General Manager, global marketing, and sales operations at Onyx Pharmaceuticals, an Amgen subsidiary. Prior to Onyx, he held several leadership positions including vice president hepatitis franchise and integrated oncology business unit at Merck & Co., global commercial leader-Procrit®/Eprex® at Ortho- Biotech, and various sales and marketing positions at Schering-Plough. Mr. Kango has served as a board member of Cancer Care of NJ, a non-profit organization for in service of patients living with cancer. Mr. Kango earned a B.S. in Microbiology and an M.B.A. from McNeese State University.